Muscle spasticity is caused by damage to the spinal cord or brain. Nerves in the brain and spinal cord help relax the muscles during the idle state. Conditions that affect the brain or spinal cord such as multiple sclerosis, cerebral palsy, and stroke can interfere with normal muscle relaxation, leading to involuntary muscle spasms. This will impair the ability to walk, work, sleep, or just function normally. The muscles can also become excessively tense and develop overactive or overresponsive reflexes. Severe cases can lead to deep disability, including an inability to straighten out joints.

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: An overview of muscle spasticity and spasms

PART 06: Pipeline landscape

PART 07: Market landscape

Market overview

Five forces analysis

PART 08: Market segmentation by product category

Skeletal muscle relaxant drugs

Facial muscle relaxant drugs

PART 09: Geographical segmentation

Muscle relaxant drugs market in Americas

Muscle relaxant drugs market in EMEA

Muscle relaxant drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

Market drivers

Impact of drivers on key customer segments

Market challenges

Impact of challenges on key customer segments

PART 12: Market trends

Anti-aging treatments driving adoption of facial

relaxants

Advanced drug delivery technologies fuels adoption of

muscle relaxants

Growing use of muscle relaxants in new indications and

applications

PART 13: Vendor landscape

Competitive scenario

PART 14: Key vendor analysis

Pfizer

Allergan

Ipsen Group

Teva Pharmaceuticals

Novartis

Other prominent vendors

PART 15: Appendix

List of abbreviations

PART 16: Explore Technavio